ACTRN12621001409864已完成1 期
A single dose, randomized, open label, pharmacokinetic study to compare the bioavailability of 5 mg bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt orally disintegrated tablet (ODT) taken sublingually against the innovator 40 mg bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt oral tablet conducted under fasting conditions in healthy volunteers.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Healthy participants
- •Aged between 18 and 55 years
- •Non-smoker
- •BMI greater than or equal to 18.5 and less than 29.9 inclusive
- •Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- •Drug free as determined by urine drug testing
- •Able to comply with the study restrictions
- •Able to provide written informed consent
排除标准
- •Asian heritage.
- •Clinically significant medical conditions
- •History of conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- •History of alcohol or drug abuse or dependency
- •Participation in a drug study within 60 days of the start of the study
- •Sensitivitie to the study drug or excipients
- •Individuals for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk
研究者
相似试验
已完成
1 期
Comparative assessment of the absorption of a generic formulation of Inhaled Insulin against the innovators Humalog KwikPen for injection and the AFREZZA Inhalation Powder Cartridge conducted under fasting conditions in healthy male and female volunteersPharmacokinetic and pharmacodynamic study conducted in healthy volunteers comparing three formulations of Insulin with no health condition or problem studied. Insulin is a medicine that is used to lower blood glucose.Pharmacokinetic and pharmacodynamic study conducted in healthy volunteers comparing three formulations of Insulin with no health condition or problem studied.Insulin is a medicine that is used to lower blood glucose.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615001100583Zenith Technology Corp Ltd21
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet against the innovator 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet conducted under fasting conditions in healthy volunteers.ACTRN12620000327987Zenith Technology Corporation Limited26
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 30 mg isotretinoin capsule against the innovator 1 x 30 mg isotretinoin capsule conducted under fed conditions in healthy male volunteers.Isotretinoin is a medicine that is used to treat severe forms of acne.Skin - Dermatological conditionsACTRN12618000935235Zenith Technology Corporation Limited32
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 40 mg isotretinoin capsule against the innovator 1 x 40 mg isotretinoin capsule conducted under fed conditions in healthy male volunteers.Isotretinoin is a medicine that is used to treat severe forms of acne.Skin - Dermatological conditionsACTRN12619000154101Zenith Technology Corp Ltd42
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 30 mg isotretinoin capsule against the innovator 1 x 30 mg isotretinoin capsules conducted under fasting conditions in healthy male volunteers.Isotretinoin is a medicine that is used to treat severe forms of acne.Skin - Dermatological conditionsACTRN12617001407381Zenith Technology Corp Ltd46